Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 01:02PM EDT. Market open.
| Previous close | 130.23 |
| Open | 130.82 |
| Bid | 130.42 x 800 |
| Ask | 130.41 x 800 |
| Day's range | 130.10 - 130.88 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,207,993 |
| Market cap | 330.494B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.98 |
| EPS (TTM) | 0.90 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | 3.08 (2.37%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 131.59 |
Simply Wall St.Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Business WireMerck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
© 2024 Yahoo. All rights reserved.